IBRX - NASDAQ
ImmunityBio, Inc.
$7.18
+0.84%ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
At a Glance
Live SnapshotImmunityBio, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
ImmunityBio, Inc. Cash Flow Statement
IBRX • NASDAQ
| ImmunityBio, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
0.0 | -413.6M | -583.9M | -416.6M | -346.8M | -224.2M | -160.2M | -96.2M | -96.4M | -120.8M | -236.9M | -6.2M | -2M | |
0.0 | 17.6M | 18.5M | 34.5M | 14.3M | 12.7M | 14M | 9.6M | 5.6M | 3.6M | 1.5M | 128K | 4K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.9M | -8K | -498K | -497K | -575K | -302K | 0.0 | 0.0 | |
0.0 | 34.4M | 49.2M | 40.2M | 57.2M | 2.2M | 3.4M | 2M | 37M | 73.9M | 211.2M | 0.0 | 0.0 | |
-250.6M | -10.2M | 145.4M | 20.3M | 16.3M | 24.1M | 6.2M | 44.6M | 50.3M | 81.7M | 212.4M | -61M | -365K | |
(0.0) | (15K) | (8K) | (0.0) | (0.0) | (8K) | (3K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-54.3M | -19.4M | 4M | -16M | -15.4M | 16.4M | -15.6M | -554K | 3.2M | 3.8M | 282K | 61M | 856K | |
-304.9M | -391.2M | -366.8M | -337.5M | -274.4M | -171.7M | -152.1M | -63.4M | -48.8M | -38.6M | -25.3M | -5.4M | -668K | |
INVESTING ACTIVITIES | |||||||||||||
-4.3M | -6.9M | -30.6M | -78.2M | -33.6M | -1.7M | -4.3M | -13.1M | -34.8M | -6.6M | -2.2M | -299K | -3K | |
(0.0) | -1M | (0.0) | (0.0) | (0.0) | (8K) | (200K) | (412K) | -32K | -137K | -1.8M | (0.0) | (0.0) | |
-241.4M | -140.2M | -10.4M | (0.0) | (0.0) | -91.8M | -87.2M | -95.5M | -119.9M | -273M | -198.1M | (0.0) | (0.0) | |
95.8M | 136.6M | 10.5M | 0.0 | 0.0 | 73.6M | 112.3M | 165.3M | 254.2M | 165.9M | 26.9M | 0.0 | 0.0 | |
0.0 | -747K | 0.0 | 105.5M | -51.3M | -8K | -2.5M | 35M | 32K | 137K | -1.8M | 0.0 | 0.0 | |
-149.8M | -12.2M | -30.5M | (27.3M) | -84.9M | -19.8M | (18.6M) | (57.1M) | (99.6M) | -113.7M | -175.2M | -299K | -3K | |
FINANCING ACTIVITIES | |||||||||||||
400.8M | 111.4M | 110.1M | -616K | -4.1M | 86.3M | 27.5M | -171K | -14M | -14.4M | 319.9M | 64.5M | 906K | |
1.7M | 96.9M | 258.6M | 174.1M | 338.5M | 63.7M | 47.7M | -477K | -19.9M | -32K | -132K | -53K | -1K | |
(0.0) | (0.0) | (0.0) | -616K | -4.1M | (0.0) | -2.5M | -228K | -15.2M | -15.8M | -4.8M | (0.0) | (0.0) | |
-2.3M | 73.4M | 189.6M | 60.2M | 171M | 673K | 39.1M | -123K | -1M | -1.1M | -2.4M | 0.0 | 0.0 | |
400.2M | 281.6M | 558.3M | 233.6M | 505.4M | 150.7M | 114.3M | -771K | -35M | -15.6M | 317.3M | 64.4M | 905K | |
CASH FLOW SUMMARY | |||||||||||||
15K | -23K | -292K | 284K | 48K | -25K | -21K | -30K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-54.5M | -121.9M | 160.8M | -76.3M | 146.2M | -40.9M | -19.3M | -7.1M | 15.8M | -167.8M | 116.8M | 58.8M | 234K | |
143.9M | 265.8M | 105M | 181.3M | 35.1M | 76M | 95.3M | 23.9M | 8.1M | 175.9M | 59.1M | 350K | 116K | |
89.4M | 143.9M | 265.8M | 105M | 181.3M | 35.1M | 76M | 16.8M | 23.9M | 8.1M | 175.9M | 59.1M | 350K | |
-308.8M | -398.1M | -397.3M | -415.7M | -308M | -173.4M | -156.4M | -76.5M | -83.6M | -45.2M | -27.5M | -5.7M | -671K |
SEC Filings
IBRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 06, 2026 | April 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 18, 2026 | February 18, 2026 | 2026 |
Related Guides
Continue your IBRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.